Medipharm Labs Earnings Call Highlights Global Growth Pivot

Medipharm Labs (Otc) ((TSE:LABS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Medipharm Labs’ latest earnings call painted a cautiously upbeat picture, with management emphasizing a return to five‑year high revenues, improving margins and a stronger balance sheet. At the same time, executives acknowledged persistent net losses, pricing pressure in key markets, and leadership transition risk, leaving investors balancing solid operational momentum against visible headwinds.

Full-Year Revenue Rebounds to Five-Year High

Medipharm reported full year 2025 revenue of $45.1 million, an 8% increase year over year and the company’s highest top line in five years. Management framed this as validation of its focused medical strategy, noting that growth was achieved despite a challenging Canadian market and selective avoidance of low‑margin opportunities.

International Medical Cannabis Becomes Growth Engine

International medical cannabis was the standout performer, growing 43% year over year and accounting for more than half of revenue across the first three quarters. In Q4, this segment climbed to 55% of total sales, underscoring how overseas medical markets have become Medipharm’s primary revenue stream and strategic focus.

Margins Strengthen on Mix and Cost Actions

The company delivered full‑year gross profit of $14.0 million, translating into a 31% gross margin as product mix and efficiency gains took hold. In Q4, gross profit reached $3.9 million with a 35% margin, up from 30% a year earlier, signaling that Medipharm is extracting more profitability from each dollar of sales.

Losses Narrow but Profitability Still Elusive

Progress toward profitability continued, with adjusted EBITDA improving to a loss of $1.6 million from a $1.9 million deficit in the prior year and net loss shrinking to $8.3 million from $10.7 million. Even so, the company remains in the red, and management conceded that a full turn to sustained profitability is still ahead rather than imminent.

Balance Sheet Strength Underpins Strategy

Medipharm closed 2025 with $10.8 million in cash, up modestly from the third quarter, and reported virtually no debt on its books. The company also owns two production facilities with a combined appraised value above $15 million, giving it tangible asset backing and financial flexibility to fund growth without overreliance on leverage.

Cost Discipline Drives Operating Expense Reductions

Operating expense control was a key theme, with total adjusted year‑to‑date operating costs down to $16.8 million, a 14% reduction versus the prior year. In the fourth quarter, adjusted operating expenses excluding severance fell 8% year over year, reflecting ongoing efforts to streamline the business while supporting core growth initiatives.

Asset Sale Funds Capacity Expansion

The company continued to reshape its footprint, completing a $4.5 million sale of its noncore Hope, British Columbia facility. Proceeds and capital were redirected into expanding EU‑GMP capacity at its Napanee site by roughly 30%, an investment that is now operational and aimed at supporting growing demand in regulated international markets.

Regulatory Credentials Create Competitive Moat

Management highlighted a robust set of regulatory and manufacturing credentials, including a Health Canada Drug Establishment license, EU‑GMP certification, and compliance with key international agencies. These approvals allow Medipharm to access tightly regulated markets and pursue pharmaceutical and B2B contracts that many competitors cannot reach.

Product Launches Broaden Global Footprint

Commercial execution advanced with first shipments into France, initial purchase orders in Brazil under an ANVISA‑licensed partner, and approvals followed by shipments to New Zealand. The product lineup also expanded with a new CBN‑THC nighttime inhaler in Canada and multiple metered dose inhalers and high‑CBD cartridges entering the Australian market.

Working Capital Managed Prudently

The company reported trade and other receivables of $7.5 million, with 85% of those balances aged 60 days or less, signaling healthy collection trends. Medipharm also remains current on excise duties, sales taxes and trade payables, which totaled $9.2 million, underscoring disciplined working capital management.

Q4 Revenue Softness Highlights Volatility

Despite full‑year growth, fourth‑quarter 2025 revenue slipped to $11.1 million from $12.0 million a year earlier, highlighting quarter‑to‑quarter variability. Management attributed the decline to timing and mix changes in its international medical business rather than underlying demand weakness, but investors will watch for sustained growth momentum.

Net Loss and EBITDA Remain in Negative Territory

While annual net loss narrowed, Medipharm still posted an $8.3 million deficit for 2025, and Q4 net loss widened to $2.0 million from $1.7 million partly due to about $1 million of severance. Adjusted EBITDA was nearly breakeven in Q4 at a loss of $0.1 million, yet remained negative for the year, emphasizing that the turnaround is not complete.

Canadian Market Dragged by Pricing and Competition

The Canadian market remained tough, with ongoing pricing pressure, fierce competition and shifting reimbursement dynamics constraining growth. Management reiterated that it is deliberately avoiding chasing low‑margin volume, sacrificing some short‑term Canadian revenue in favor of protecting margins and long‑term profitability.

International Pricing and Regulatory Headwinds

Beyond Canada, Medipharm is contending with pricing compression in Germany and Australia as more players enter these markets. Potential regulatory shifts and tighter enforcement, such as changes in consultation rules in Germany, may further pressure prices and require careful navigation to maintain profitability.

Veteran Affairs Reimbursement Cut Looms

A significant future headwind comes from Veteran Affairs Canada, which plans to lower its maximum reimbursable cannabis price per gram in 2026. Management warned that this change is expected to weigh on direct‑to‑patient revenue from the second quarter of that year, adding another layer of pressure to domestic earnings.

Leadership Transition Adds Governance Uncertainty

The company is also managing executive changes as its CEO has stepped down and the CFO steps in as interim leader while the board searches for a permanent replacement. This transition introduces governance uncertainty at a critical stage in Medipharm’s evolution, even as underlying operations show improving trends.

One-Time Costs Skewed 2025 Results

Reported 2025 numbers were affected by discrete items, including $2.5 million of proxy contest expenses and $1.3 million in severance. Management argued that these one‑time costs obscure the underlying improvement in operations, making adjusted figures a more accurate reflection of the company’s trajectory.

Focus on International Growth and Disciplined Expansion

Looking ahead, Medipharm avoided issuing formal 2026 guidance but laid out clear priorities centered on growing international medical revenue in Germany, the U.K., New Zealand, Brazil, France and Australia. The company aims to build global brands, selectively expand pharmaceutical and B2B channels where returns justify investment, and maintain strict cost discipline while navigating known reimbursement headwinds.

Medipharm’s earnings call conveyed a company that has regained top‑line momentum, strengthened margins and fortified its balance sheet, yet still faces profitability, pricing and leadership challenges. For investors, the story hinges on whether international medical growth and disciplined execution can offset regulatory and reimbursement pressures and ultimately carry the business into sustainable profit.